tipifarnib has been researched along with methionine in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (methionine) | Trials (methionine) | Recent Studies (post-2010) (methionine) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 27,485 | 530 | 5,020 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berk, S; Gajewski, TF; Ho, AW; Kuna, T; Marks, RE; Robbel, C | 1 |
1 other study(ies) available for tipifarnib and methionine
| Article | Year |
|---|---|
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
Topics: Antibodies, Monoclonal; Blotting, Western; CD28 Antigens; CD3 Complex; Cells, Cultured; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; HSP40 Heat-Shock Proteins; Humans; Interferon-gamma; Interleukin-2; Interleukin-4; Lymphocyte Activation; MAP Kinase Kinase 4; Methionine; Phosphorylation; Piperidines; Protein Prenylation; Pyridines; Quinolones; Ribonuclease, Pancreatic; Ribosomal Protein S6 Kinases, 70-kDa; RNA Processing, Post-Transcriptional; T-Lymphocytes; Th1 Cells; Th2 Cells | 2007 |